Can I use direct oral anticoagulants to treat cancer-associated venous thromboembolism?

[摘要] Yes. The direct oral anticoagulants rivaroxaban, edoxaban, and apixaban have been studied in cancer-associated venous thromboembolism and are increasingly replacing low-molecular-weight heparins such as dalteparin and enoxaparin for this purpose. Individualizing care by balancing risks and benefits for each patient will help in choosing the right anticoagulant.

[学科分类] 卫生学